

Prof. Dr. Dirk Jäger

Director Dept. of Medical Oncology, National Center for Tumor Diseases Heidelberg



1.8.1964

National Center for Tumor Diseases
University of Heidelberg
Im Neuenheimer Feld 350
69120 Heidelberg

06221 56 7229 (phone)

06221 56 7225 (fax)

dirk.jaeger@med.uni-heidelberg.de

SCIENTIFIC VITA:

- 1998–2000 Postdoctoral Fellowship (Cancer Research Institute) Cornell Medical Center: Identification and characterization of tumor-associated antigens in melanoma and breast cancer using the SEREX approach (Y.T.- Chen)
- 2000–2003 Group leader of the Antigen Discovery Program at Krankenhaus Nordwest, Frankfurt (Director: Alexander Knuth)
- 2003–2005 Attending Physician at the Department of Oncology, University Hospital Zurich, Switzerland (Director: Alexander Knuth) Leader of the Laboratory for Tumor Immunology, Coordinator of the Clinical Trials Center Zurich as part of the Ludwig Institute for Cancer Research
- 2005 Director of the Medical Oncology Department, National Center for Tumor Diseases, University Hospital Heidelberg
- 2006 Official Affiliation with the Ludwig Institute for Cancer Research

AWARDS:

Rose-Marie-Finnell Memorial Fellowship for Breast Cancer Research (1998); Since 2000 Member of the Antigen Discovery Program, Cancer Research Institute, New York and Ludwig Institute for Cancer Research, New York; AVON Award for breast cancer research, Cancer Research Institute, NY, 2001; Investigators Award, Cancer Research Institute, New York, 2006.

FIELDS OF INTEREST:

Analysis of spontaneous interactions of the immune system with developing tumors. Identification and characterization of tumor-associated antigens in different tumor types as potential targets for immunotherapy approaches using a serological cloning strategy (SEREX). Characterization of tumor-associated antigens and validation for T-cell based as well as antibody based therapies. Functional characterization of tumor associated antigens: implications for therapeutic strategies. Evaluation of potential target antigens in clinical trials (antibodies, vaccines). Analysis of spontaneous humoral and cellular immune responses in cancer patients as potential prognostic and diagnostic markers in different tumor types.

SELECTED PUBLICATIONS (SINCE 2000)

Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E., Ritter G, Jager D, Panicali D, Hoffman E, Pan L, Oettgen H., Old LJ, Knuth A (2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. **Proc Natl Acad Sci U S A** 103, 14453-14458

Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schafer N, Urosevic M, Dummer R, Tiercy JM, Mackensen A, Jaeger E, Levy F, Knuth A, Jager D, Zippelius A (2006). Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. **J Immunol** 177, 8212-8218

Halama N, Grauling-Halama SA, Jager D (2006). Identification and characterization of the human StARD9 gene in the LGMD2A-region on chromosome 15q15 by in silico methods. **Int J Mol Med** 18, 653-656

Zippelius A, Gati A, Bartnick T, Walton S, Odermatt B, Jaeger E, Dummer R, Urosevic M, Filonenko V, Osanai K, Moch H, Chen YT, Old LJ, Knuth A, and Jaeger D (2007). Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. **Cancer Immunol Immunother** 56, 249-258 [Epub 2006 May 23]

Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen YT, Old, LJ, Knuth A, Jager D.* Moch H (2006). Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. **Clin Cancer Res** 12, 2745-2751 [* shared senior authorship]

Jager D, Karbach J, Pauligk C, Seil I, Frei C, Chen YT, Old LJ, Knuth A, Jager E (2005). Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes. **Cancer Immun** 5, 11

Jager D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jager E, Knuth A, Old LJ, Chen YT (2001). Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. **Cancer Res** 61, 2055-2061

Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ (2000). The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. **Cell** 103, 757-768

Jager D, Stockert E, Jager E, Gure AO, Scanlan MJ, Knuth A, Old LJ, Chen YT (2000). Serological cloning of a melanocyte rab guanosine 5'-triphosphate-binding protein and a chromosome condensation protein from a melanoma complementary DNA library. **Cancer Res** 60, 3584-3591

Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000). Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. **J Exp Med** 191, 625-630